Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetic study of STN1012600 ophthalmic solution in healthy adult male volunteers
jRCT2051230035Phase 1Completed
- Sponsor
- Santen Pharmaceutical
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sepetaprost in open-angle glaucoma (OAG) and ocular hypertension, sponsored by Santen Pharmaceutical. Primary endpoint: Plasma pharmacokinetics of STN1012600. Started Jun 2023; status: completed.
02
Drugs
sepetaprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on jRCT2051230035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230035.